These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 22020350)

  • 1. Aripiprazole and dehydroaripiprazole plasma concentrations and clinical responses in patients with schizophrenia.
    Lin SK; Chen CK; Liu YL
    J Clin Psychopharmacol; 2011 Dec; 31(6):758-62. PubMed ID: 22020350
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of paroxetine on plasma concentrations of aripiprazole and its active metabolite, dehydroaripiprazole, in Japanese patients with schizophrenia.
    Nemoto K; Mihara K; Nakamura A; Nagai G; Kagawa S; Suzuki T; Kondo T
    Ther Drug Monit; 2012 Apr; 34(2):188-92. PubMed ID: 22377745
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of genetic polymorphisms of CYP2D6, CYP3A5, and ABCB1 on the steady-state plasma concentrations of aripiprazole and its active metabolite, dehydroaripiprazole, in Japanese patients with schizophrenia.
    Suzuki T; Mihara K; Nakamura A; Kagawa S; Nagai G; Nemoto K; Kondo T
    Ther Drug Monit; 2014 Oct; 36(5):651-5. PubMed ID: 24682161
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prediction of an Optimal Dose of Aripiprazole in the Treatment of Schizophrenia From Plasma Concentrations of Aripiprazole Plus Its Active Metabolite Dehydroaripiprazole at Week 1.
    Nagai G; Mihara K; Nakamura A; Nemoto K; Kagawa S; Suzuki T; Kondo T
    Ther Drug Monit; 2017 Feb; 39(1):62-65. PubMed ID: 27861318
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of the CYP2D6*10 allele on the steady-state plasma concentrations of aripiprazole and its active metabolite, dehydroaripiprazole, in Japanese patients with schizophrenia.
    Suzuki T; Mihara K; Nakamura A; Nagai G; Kagawa S; Nemoto K; Ohta I; Arakaki H; Uno T; Kondo T
    Ther Drug Monit; 2011 Feb; 33(1):21-4. PubMed ID: 21157400
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CYP1A2*F Polymorphism Contributes at Least Partially to the Variability of Plasma Levels of Dehydroaripiprazole, an Active Metabolite of Aripiprazole, in Schizophrenic Patients.
    Suzuki T; Nagai G; Mihara K; Tomori Y; Kagawa S; Nakamura A; Nemoto K; Kondo T
    Drug Metab Bioanal Lett; 2024; 17(1):7-12. PubMed ID: 37855290
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Aripiprazole: a review of its use in schizophrenia and schizoaffective disorder.
    Swainston Harrison T; Perry CM
    Drugs; 2004; 64(15):1715-36. PubMed ID: 15257633
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intramuscular aripiprazole in the acute management of psychomotor agitation.
    De Filippis S; Cuomo I; Lionetto L; Janiri D; Simmaco M; Caloro M; De Persis S; Piazzi G; Simonetti A; Telesforo CL; Sciarretta A; Caccia F; Gentile G; Kotzalidis GD; Girardi P
    Pharmacotherapy; 2013 Jun; 33(6):603-14. PubMed ID: 23505124
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Serum levels of aripiprazole and dehydroaripiprazole, clinical response and side effects.
    Kirschbaum KM; Müller MJ; Malevani J; Mobascher A; Burchardt C; Piel M; Hiemke C
    World J Biol Psychiatry; 2008; 9(3):212-8. PubMed ID: 17853280
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Population pharmacokinetic modelling of aripiprazole and its active metabolite, dehydroaripiprazole, in psychiatric patients.
    Kim JR; Seo HB; Cho JY; Kang DH; Kim YK; Bahk WM; Yu KS; Shin SG; Kwon JS; Jang IJ
    Br J Clin Pharmacol; 2008 Dec; 66(6):802-10. PubMed ID: 19032724
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetic variability of aripiprazole and the active metabolite dehydroaripiprazole in psychiatric patients.
    Molden E; Lunde H; Lunder N; Refsum H
    Ther Drug Monit; 2006 Dec; 28(6):744-9. PubMed ID: 17164689
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Aripiprazole: in adolescents with schizophrenia.
    Sanford M; Keating GM
    Paediatr Drugs; 2007; 9(6):419-23. PubMed ID: 18052412
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Olanzapine versus aripiprazole for the treatment of agitation in acutely ill patients with schizophrenia.
    Kinon BJ; Stauffer VL; Kollack-Walker S; Chen L; Sniadecki J
    J Clin Psychopharmacol; 2008 Dec; 28(6):601-7. PubMed ID: 19011427
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Changes in positive and negative syndrome scale-derived hostility factor in adolescents with schizophrenia treated with aripiprazole: post hoc analysis of randomized clinical trial data.
    Robb AS; Carson WH; Nyilas M; Ali M; Forbes RA; Iwamoto T; Assunção-Talbott S; Whitehead R; Pikalov A
    J Child Adolesc Psychopharmacol; 2010 Feb; 20(1):33-8. PubMed ID: 20166794
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetics, tolerability and safety of aripiprazole once-monthly in adult schizophrenia: an open-label, parallel-arm, multiple-dose study.
    Mallikaarjun S; Kane JM; Bricmont P; McQuade R; Carson W; Sanchez R; Forbes RA; Fleischhacker WW
    Schizophr Res; 2013 Oct; 150(1):281-8. PubMed ID: 23890595
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Large variability of aripiprazole and dehydroaripiprazole serum concentrations in adolescent patients with schizophrenia.
    Bachmann CJ; Rieger-Gies A; Heinzel-Gutenbrunner M; Hiemke C; Remschmidt H; Theisen FM
    Ther Drug Monit; 2008 Aug; 30(4):462-6. PubMed ID: 18641558
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lack of correlation between the steady-state plasma concentrations of aripiprazole and haloperidol in Japanese patients with schizophrenia.
    Nakamura A; Mihara K; Nemoto K; Nagai G; Kagawa S; Suzuki T; Kondo T
    Ther Drug Monit; 2014 Dec; 36(6):815-8. PubMed ID: 24739668
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Simultaneous determination of aripiprazole and its active metabolite, dehydroaripiprazole, in plasma by capillary electrophoresis combining on-column field-amplified sample injection and application in schizophrenia.
    Hwang PL; Wei SY; Yeh HH; Ko JY; Chang CC; Chen SH
    Electrophoresis; 2010 Aug; 31(16):2778-86. PubMed ID: 20665528
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetics of aripiprazole and concomitant carbamazepine.
    Citrome L; Macher JP; Salazar DE; Mallikaarjun S; Boulton DW
    J Clin Psychopharmacol; 2007 Jun; 27(3):279-83. PubMed ID: 17502775
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Aripiprazole.
    Winans E
    Am J Health Syst Pharm; 2003 Dec; 60(23):2437-45. PubMed ID: 14686220
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.